Clinical Trials Browser

NIH × pembrolizumab × Lymphoid × Clear all

NCT03204188 2026-01-30

Ibrutinib, Fludarabine, and Pembrolizumab in High-Risk or Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Phase 2 Completed

15 enrolled 9 charts

LymphoidOther hematologic neoplasm

Chromosome 17 deletion, Leukemia, Lymphocytic, Chronic, B-Cell

NCT02595866 2024-08-09

Testing the Addition of an Experimental Medication MK-3475 (Pembrolizumab) to Usual Anti-Retroviral Medications in Patients With HIV and Cancer

Phase 1 Completed

58 enrolled 17 charts

DermatologicGastrointestinalLymphoidSarcomaThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Hepatocellular, Lung Neoplasms, Lymphoma, Non-Hodgkin, Melanoma, Neoplasm Metastasis, Neoplasms, Recurrence, Sarcoma, Kaposi, HIV Infections

NCT03255018 2023-11-28

Pembrolizumab in Relapsed and Refractory Gray-Zone Lymphoma (GZL), Primary Central Nervous System Lymphoma (PCNSL), and Other Extranodal Diffuse Large B-cell Lymphomas

Phase 2 Completed

12 enrolled 21 charts

Lymphoid

Lymphoma, Lymphoma, Non-Hodgkin, Lymphoma, Large B-Cell, Diffuse

NCT03063632 2023-10-25

Testing the Combination of Two Experimental Drugs MK-3475 (Pembrolizumab) and Interferon-gamma for the Treatment of Mycosis Fungoides and Sézary Syndrome and Advanced Synovial Sarcoma

Phase 2 Completed

28 enrolled 15 charts

LymphoidSarcoma

Mycosis Fungoides, Sezary Syndrome, Sarcoma, Synovial, Liposarcoma, Myxoid

NCT03309878 2023-09-21

Mogamulizumab and Pembrolizumab in Treating Patients With Relapsed or Refractory Diffuse Large B Cell Lymphoma

Phase 1/2 Completed

8 enrolled 10 charts

Lymphoid

Lymphoma, Large B-Cell, Diffuse

NCT02243579 2019-09-20

Pembrolizumab in Treating Patients With Relapsed or Refractory Stage IB-IVB Mycosis Fungoides or Sezary Syndrome

Phase 2 Completed

24 enrolled 13 charts

Lymphoid

Mycosis Fungoides, Sezary Syndrome